Smith Asset Management Group LP reduced its stake in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 5.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,690 shares of the medical research company’s stock after selling 3,425 shares during the quarter. Smith Asset Management Group LP owned approximately 0.09% of PRA Health Sciences worth $4,394,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. First Bank & Trust increased its position in PRA Health Sciences by 1.6% during the 2nd quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock valued at $241,000 after purchasing an additional 52 shares during the period. Renaissance Group LLC increased its position in PRA Health Sciences by 2.5% during the 2nd quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock valued at $393,000 after purchasing an additional 126 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in PRA Health Sciences by 12.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 160 shares during the period. Los Angeles Capital Management & Equity Research Inc. increased its position in PRA Health Sciences by 1.9% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock valued at $638,000 after purchasing an additional 160 shares during the period. Finally, Eqis Capital Management Inc. boosted its holdings in shares of PRA Health Sciences by 6.5% during the 2nd quarter. Eqis Capital Management Inc. now owns 4,217 shares of the medical research company’s stock valued at $316,000 after buying an additional 259 shares in the last quarter. 97.24% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently commented on PRAH. SunTrust Banks, Inc. restated a “buy” rating on shares of PRA Health Sciences in a report on Wednesday, August 9th. Credit Suisse Group boosted their target price on shares of PRA Health Sciences from $80.00 to $84.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Robert W. Baird boosted their target price on shares of PRA Health Sciences from $82.00 to $83.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Citigroup Inc. restated a “buy” rating and set a $93.00 target price (up previously from $90.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. Finally, Jefferies Group LLC restated a “buy” rating and set a $92.00 target price (up previously from $88.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $88.09.

ILLEGAL ACTIVITY WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/11/09/pra-health-sciences-inc-prah-shares-sold-by-smith-asset-management-group-lp.html.

In other PRA Health Sciences news, CEO Colin Shannon sold 400,000 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $29,940,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Linda Baddour sold 100,000 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $7,485,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 10,000,000 shares of company stock valued at $748,500,000. 2.10% of the stock is owned by insiders.

Shares of PRA Health Sciences, Inc. (PRAH) traded down $3.40 during trading on Thursday, reaching $80.10. 135,739 shares of the company were exchanged, compared to its average volume of 493,378. The company has a market cap of $5,274.90, a PE ratio of 30.60, a price-to-earnings-growth ratio of 1.44 and a beta of 0.43. PRA Health Sciences, Inc. has a 52 week low of $51.16 and a 52 week high of $84.38. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The company had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same quarter in the previous year, the business posted $0.64 EPS. PRA Health Sciences’s revenue was up 23.7% compared to the same quarter last year. research analysts anticipate that PRA Health Sciences, Inc. will post 3.2 earnings per share for the current fiscal year.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.